Subscribe

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

LATE-BREAKING RESEARCH: Practice Management Research
Abstract #LB03

Evaluation of the Reliability of 5-FU Elastomeric Pump in an Ambulatory Infusion Center

JHOP - March 2022 Vol 12 Special Feature - HOPA Abstracts

Presenter: Quan Li, PharmD, BCOP, BCPS, Clinical Coordinator, MedStar Washington Hospital Center, Washington, DC

Co-Author: Alice Beers, BSN, OCN, NPD-BC, MedStar Washington Hospital Center, Washington, DC

BACKGROUND: Continuous infusion of fluorouracil (5-FU) is often used in the treatment of gastrointestinal (GI) malignancies through an ambulatory infusion pump.1,2 However, the infusion rate of elastomeric pumps is affected by environmental and patient factors.3,4 Monitoring drug delivery by the pump is essential to treatment efficiency and drug safety.5 Visual inspection, as recommended in the package insert, is not reliable. A quantitative method to assess the delivery of 5-FU via an elastomeric pump is in great need. Recently, Cusano and colleagues showed the feasibility to monitor 5-FU delivery via Baxter elastomeric pump by comparing pump weights before and after infusion.6 However, more than 24% of the pumps had remaining fluid of >10%, suggesting insufficient delivery of the elastomeric pumps.6,7

OBJECTIVE: To evaluate the reliability of SMARTeZ elastomeric pump to deliver 5-FU, by measuring the percentage of pumps that deliver >90% of expected 5-FU dose at the end of 46 hours of infusion.

METHOD: This retrospective chart-review study included patients who were at least 18 years old, diagnosed with GI cancer and treated with intravenous 5-FU continuous infusion over 46 hours through elastomeric pump between April 1, 2021, and September 30, 2021. Pregnant females or patients younger than 18 years old were excluded. The primary end point was the reliability of the 5-FU elastomeric pump, measured by the percentage of elastomeric pumps delivering >90% of expected 5-FU doses. Secondary end points included the average percentage of 5-FU delivery of each pump, the average weight of empty, and full and returned empty pump.

RESULTS: A total of 24 patients and 117 pumps were included in the analysis. Overall, 95.7% of the patients received >90% of expected 5-FU dose. The average percentage of 5-FU delivery was 94.9% ± 7.3%. The average weight of empty, full, and returned pumps was 92.9 g ± 1.3 g, 335.1 g ± 1.5 g, and 105.4 g ± 17.7 g, respectively.

CONCLUSION: SMARTeZ elastomeric pumps were reliable to deliver 5-FU continuous infusion over 46 hours for patients with cancer.

  1. Sabbagh Dit Hawasli R, Barton S, Nabhani-Gebara S. Ambulatory chemotherapy: past, present, and future. J Oncol Pharm Pract. 2021;27:962-973.
  2. Backler C. Which ambulatory infusion pump is best for 5-FU? April 18, 2019. ONS Voice. https://voice.ons.org/news-and-views/which-ambulatory-infusion-pump-is-best-for-5-fu. Accessed July 31, 2021.
  3. Salman D, Biliune J, Kayyali R, et al. Evaluation of the performance of elastomeric pumps in practice: are we under-delivering on chemotherapy treatments? Curr Med Res Opin. 2017;33:2153-2159.
  4. Abe T, Matsuzaka K, Nakayama T, et al. Impact of air temperature and drug concentration on liquid emission from elastomeric pumps. J Pharm Health Care Sci. 2021;7:1. doi: 10.1186/s40780-020-00185-5.
  5. Institute for Safe Medication Practices. Accidental overdoses involving fluorouracil infusions. June 18, 2015. www.ismp.org/resources/accidental-overdoses-involving-fluorouracil-infusions. Accessed August 31, 2021.
  6. Cusano EL, Ali R, Sawyer MB, et al. Baxter elastomeric pumps: weighing as an alternative to visual inspection. J Oncol Pharm Pract. 2018;24:163-169.
  7. Chambers CR, Pabia M, Sawyer M, Tang PA. Baxter elastomeric pumps: feasibility of weight estimates. J Oncol Pharm Pract. 2017;23:429-435.
Related Items
HOP(A) Springs Eternal
Bryna Delman Ewachiw, PharmD, BCOP, Mark L. Zangardi, PharmD, BCOP
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in Editorial, HOPA Abstracts
A Pooled Safety Analysis of Loncastuximab Tesirine in Relapsed or Refractory DLBCL in the LOTIS Clinical Trial Program: Incidence, Onset, and Management of Myelosuppression
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts, Lymphoma
Evaluation of Empiric Double Coverage with Tobramycin for Adult Patients with Febrile Neutropenia
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts
Treatment Patterns, Real-World Outcomes, and Resource Use in Patients with Non–MSI-High or Mismatch Repair Proficient Advanced Endometrial Cancer
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts, Gynecologic Cancers
Development and Implementation of a Pharmacist-Led Virtual Clinic Improve the Management of Patients with Metastatic Breast Cancer Receiving CDK4/6 Inhibitors
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts, Breast Cancer
Impact of a Remote Oncology Clinical Pharmacist Program in 4 Community Oncology Practices
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts
Impact of PGY2 Oncology Pharmacy Residents’ Learning Experiences During the COVID-19 Pandemic
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts
Integrated Health-System Specialty Pharmacy Support in Reducing Financial Toxicity of Oral Oncolytic Therapy
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts
Perceptions of PGY2 Oncology Programs on Financial Toxicity Education and Preparedness
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts
Pharmacist-Led Oral Chemotherapy Monitoring Pilot Study and Assessment of Patient-Reported Outcomes and Adherence
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts, Chemotherapy
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.